Induction of partial protection against infection with Toxoplasma gondii genotype II by DNA vaccination with recombinant chimeric tachyzoite antigens

Vaccine

Volumn 27, Issue 18, 2009, Pages 2489-2498

  Rosenberg, Carina ^a,e   De Craeye, Stéphane ^b   Jongert, Erik ^b   Gargano, Nicola ^c   Beghetto, Elisa ^c   Del Porto, Paola ^d   Vorup Jensen, Thomas ^e   Petersen, Eskild ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^c Kenton Laboratories   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e AARHUS UNIVERSITY   (Denmark)

Author keywords

Cellular immunity; DNA vaccination; Toxoplasma gondii

Indexed keywords

ANTIGEN; CHIMERIC PROTEIN; EC2 ANTIGEN; EC3 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOPLASM; DNA IMMUNIZATION; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SEQUENCE ANALYSIS; SPLEEN CELL; TACHYZOITE; TOXOPLASMA GONDII; TOXOPLASMOSIS;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CYTOKINES; FEMALE; GENOTYPE; HUMANS; MICE; MICE, INBRED BALB C; PROTOZOAN VACCINES; RECOMBINANT FUSION PROTEINS; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL; VACCINATION; VACCINES, DNA;

EID: 62749152714     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.02.058     Document Type: Article

References (62)

1. Petersen E., and Liesenfeld O. Clinical disease and diagnosis of Toxoplasma gondii. In: Weiss L.M., and Kim K. (Eds). Toxoplasma Gondii-the model apicomplexan: perspectives and methods (2007), Academic Press, Elsevier 81-94
2. Boothroyd J.C., and Grigg M.E. Population biology of Toxoplasma gondii and its relevance to human infection: do different strains cause different disease?. Curr Opin Microbiol 5 4 (2002) 438-442
3. Khan A., Fux B., Su C., Dubey J.P., Darde M.L., Ajioka J.W., et al. Recent transcontinental sweep of Toxoplasma gondii driven by a single monomorphic chromosome. Proc Natl Acad Sci U S A 104 37 (2007) 14872-14877
4. Peyron F., Lobry J.R., Musset K., Ferrandiz J., Gomez-Marin J.E., Petersen E., et al. Serotyping of Toxoplasma gondii in chronically infected pregnant women: predominance of type II in Europe and types I and III in Colombia (South America). Microbes Infect 8 9-10 (2006) 2333-2340
5. Khan A., Jordan C., Muccioli C., Vallochi A.L., Rizzo L.V., Belfort Jr. R., et al. Genetic divergence of Toxoplasma gondii strains associated with ocular toxoplasmosis, Brazil. Emerg Infect Dis 12 6 (2006) 942-949
6. Lehmann T., Marcet P.L., Graham D.H., Dahl E.R., and Dubey J.P. Globalization and the population structure of Toxoplasma gondii. Proc Natl Acad Sci U S A 103 30 (2006) 11423-11428
7. Havelaar A.H., Kemmeren J.M., and Kortbeek L.M. Disease burden of congenital toxoplasmosis. Clin Infect Dis 44 11 (2007) 1467-1474
8. Martino R., Bretagne S., Einsele H., Maertens J., Ullmann A.J., Parody R., et al. Early detection of Toxoplasma infection by molecular monitoring of Toxoplasma gondii in peripheral blood samples after allogeneic stem cell transplantation. Clin Infect Dis 40 1 (2005) 67-78
9. Denkers E.Y., and Gazzinelli R.T. Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clin Microbiol Rev 11 4 (1998) 569-588
10. Liu M.A., and Ulmer J.B. Human clinical trials of plasmid DNA vaccines. Adv Genet 55 (2005) 25-40
11. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20 (2002) 709-760
12. Bogdan C., and Rollinghoff M. The immune response to Leishmania: mechanisms of parasite control and evasion. Int J Parasitol 28 1 (1998) 121-134
13. Salgame P. Host innate and Th1 responses and the bacterial factors that control Mycobacterium tuberculosis infection. Curr Opin Immunol 17 4 (2005) 374-380
14. Nielsen H.V., Di Cristina M., Beghetto E., Spadoni A., Petersen E., and Gargano N. Toxoplasma gondii: DNA vaccination with bradyzoite antigens induces protective immunity in mice against oral infection with parasite cysts. Exp Parasitol 112 4 (2006) 274-279
15. Angus C.W., Klivington-Evans D., Dubey J.P., and Kovacs J.A. Immunization with a DNA plasmid encoding the SAG1 (P30) protein of Toxoplasma gondii is immunogenic and protective in rodents. J Infect Dis 181 1 (2000) 317-324
16. Desolme B., Mevelec M.N., Buzoni-Gatel D., and Bout D. Induction of protective immunity against toxoplasmosis in mice by DNA immunization with a plasmid encoding Toxoplasma gondii GRA4 gene. Vaccine 18 23 (2000) 2512-2521
17. Ismael A.B., Sekkai D., Collin C., Bout D., and Mevelec M.N. The MIC3 gene of Toxoplasma gondii is a novel potent vaccine candidate against toxoplasmosis. Infect Immun 71 11 (2003) 6222-6228
18. Scorza T., D'Souza S., Laloup M., Dewit J., De Braekeleer J., Verschueren H., et al. A GRA1 DNA vaccine primes cytolytic CD8(+) T cells to control acute Toxoplasma gondii infection. Infect Immun 71 1 (2003) 309-316
19. Dautu G., Munyaka B., Carmen G., Zhang G., Omata Y., Xuenan X., et al. Toxoplasma gondii: DNA vaccination with genes encoding antigens MIC2, M2AP, AMA1 and BAG1 and evaluation of their immunogenic potential. Exp Parasitol 116 3 (2007) 273-282
20. Vercammen M., Scorza T., Huygen K., De Braekeleer J., Diet R., Jacobs D., et al. DNA vaccination with genes encoding Toxoplasma gondii antigens GRA1, GRA7, and ROP2 induces partially protective immunity against lethal challenge in mice. Infect Immun 68 1 (2000) 38-45
21. Jongert E., de Craeye S., Dewit J., and Huygen K. GRA7 provides protective immunity in cocktail DNA vaccines against Toxoplasma gondii. Parasite Immunol 29 9 (2007) 445-453
22. Hershko A., and Ciechanover A. The ubiquitin system. Annu Rev Biochem 67 (1998) 425-479
23. Yewdell J.W., Anton L.C., and Bennink J.R. Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules?. J Immunol 157 5 (1996) 1823-1826
24. Asher G., Reuven N., and Shaul Y. 20S proteasomes and protein degradation "by default". Bioessays 28 8 (2006) 844-849
25. Townsend A., Bastin J., Gould K., Brownlee G., Andrew M., Coupar B., et al. Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J Exp Med 168 4 (1988) 1211-1224
26. Andersson H.A., and Barry M.A. Maximizing antigen targeting to the proteasome for gene-based vaccines. Mol Ther 10 3 (2004) 432-446
27. Ishii K., Hisaeda H., Duan X., Imai T., Sakai T., Fehling H.J., et al. The involvement of immunoproteasomes in induction of MHC class I-restricted immunity targeting Toxoplasma SAG1. Microbes Infect 8 4 (2006) 1045-1053
28. Beghetto E., Spadoni A., Bruno L., Buffolano W., and Gargano N. Chimeric antigens of Toxoplasma gondii: toward standardization of toxoplasmosis serodiagnosis using recombinant products. J Clin Microbiol 44 6 (2006) 2133-2140
29. Roberts C.W., and Alexander J. Studies on a murine model of congenital toxoplasmosis: vertical disease transmission only occurs in BALB/c mice infected for the first time during pregnancy. Parasitology 104 Pt 1 (1992) 19-23
30. Roberts C.W., Brewer J.M., and Alexander J. Congenital toxoplasmosis in the Balb/c mouse: prevention of vertical disease transmission and fetal death by vaccination. Vaccine 12 15 (1994) 1389-1394
31. Beghetto E., Spadoni A., Buffolano W., Del Pezzo M., Minenkova O., Pavoni E., et al. Molecular dissection of the human B-cell response against Toxoplasma gondii infection by lambda display of cDNA libraries. Int J Parasitol 33 2 (2003) 163-173
32. Homan W.L., Vercammen M., De Braekeleer J., and Verschueren H. Identification of a 200- to 300-fold repetitive 529 bp DNA fragment in Toxoplasma gondii, and its use for diagnostic and quantitative PCR. Int J Parasitol 30 1 (2000) 69-75
33. Kijlstra A., Meerburg B., Cornelissen J., De Craeye S., Vereijken P., and Jongert E. The role of rodents and shrews in the transmission of Toxoplasma gondii to pigs. Vet Parasitol (2008)
34. Jones D.T. Protein secondary structure prediction based on position-specific scoring matrices. J Mol Biol 292 2 (1999) 195-202
35. McGuffin L.J., Bryson K., and Jones D.T. The PSIPRED protein structure prediction server. Bioinformatics 16 4 (2000) 404-405
36. Wang J., Dauter M., Alkire R., Joachimiak A., and Dauter Z. Triclinic lysozyme at 0.65 A resolution. Acta Crystallogr D Biol Crystallogr 63 Pt 12 (2007) 1254-1268
37. Nielsen H.V., Lauemoller S.L., Christiansen L., Buus S., Fomsgaard A., and Petersen E. Complete protection against lethal Toxoplasma gondii infection in mice immunized with a plasmid encoding the SAG1 gene. Infect Immun 67 12 (1999) 6358-6363
38. Fachado A., Rodriguez A., Angel S.O., Pinto D.C., Vila I., Acosta A., et al. Protective effect of a naked DNA vaccine cocktail against lethal toxoplasmosis in mice. Vaccine 21 13-14 (2003) 1327-1335
39. Beghetto E., Nielsen H.V., Del Porto P., Buffolano W., Guglietta S., Felici F., et al. A combination of antigenic regions of Toxoplasma gondii microneme proteins induces protective immunity against oral infection with parasite cysts. J Infect Dis 191 4 (2005) 637-645
40. Mevelec M.N., Bout D., Desolme B., Marchand H., Magne R., Bruneel O., et al. Evaluation of protective effect of DNA vaccination with genes encoding antigens GRA4 and SAG1 associated with GM-CSF plasmid, against acute, chronical and congenital toxoplasmosis in mice. Vaccine 23 36 (2005) 4489-4499
41. Xue M., He S., Cui Y., Yao Y., and Wang H. Evaluation of the immune response elicited by multi-antigenic DNA vaccine expressing SAG1, ROP2 and GRA2 against Toxoplasma gondii. Parasitol Int (2008)
42. Zhang G., Huong V.T., Battur B., Zhou J., Zhang H., Liao M., et al. A heterologous prime-boost vaccination regime using DNA and a vaccinia virus, both expressing GRA4, induced protective immunity against Toxoplasma gondii infection in mice. Parasitology 134 Pt 10 (2007) 1339-1346
43. Mineo J.R., and Kasper L.H. Attachment of Toxoplasma gondii to host cells involves major surface protein, SAG-1 (P30). Exp Parasitol 79 1 (1994) 11-20
44. Garcia-Reguet N., Lebrun M., Fourmaux M.N., Mercereau-Puijalon O., Mann T., Beckers C.J., et al. The microneme protein MIC3 of Toxoplasma gondii is a secretory adhesin that binds to both the surface of the host cells and the surface of the parasite. Cell Microbiol 2 4 (2000) 353-364
45. Huynh M.H., Rabenau K.E., Harper J.M., Beatty W.L., Sibley L.D., and Carruthers V.B. Rapid invasion of host cells by Toxoplasma requires secretion of the MIC2-M2AP adhesive protein complex. EMBO J 22 9 (2003) 2082-2090
46. Harper J.M., Huynh M.H., Coppens I., Parussini F., Moreno S., and Carruthers V.B. A cleavable propeptide influences Toxoplasma infection by facilitating the trafficking and secretion of the TgMIC2-M2AP invasion complex. Mol Biol Cell 17 10 (2006) 4551-4563
47. Fischer H.G., Stachelhaus S., Sahm M., Meyer H.E., and Reichmann G. GRA7, an excretory 29 kDa Toxoplasma gondii dense granule antigen released by infected host cells. Mol Biochem Parasitol 91 2 (1998) 251-262
48. Henriquez F.L., Nickdel M.B., McLeod R., Lyons R.E., Lyons K., Dubremetz J.F., et al. Toxoplasma gondii dense granule protein 3 (GRA3) is a type I transmembrane protein that possesses a cytoplasmic dilysine (KKXX) endoplasmic reticulum (ER) retrieval motif. Parasitology 131 Pt 2 (2005) 169-179
49. Asher G., and Shaul Y. P53 proteasomal degradation: poly-ubiquitination is not the whole story. Cell Cycle 4 8 (2005) 1015-1018
50. Ostankovitch M., Robila V., and Engelhard V.H. Regulated folding of tyrosinase in the endoplasmic reticulum demonstrates that misfolded full-length proteins are efficient substrates for class I processing and presentation. J Immunol 174 5 (2005) 2544-2551
51. York I.A., Goldberg A.L., Mo X.Y., and Rock K.L. Proteolysis and class I major histocompatibility complex antigen presentation. Immunol Rev 172 (1999) 49-66
52. Turner G.C., and Varshavsky A. Detecting and measuring cotranslational protein degradation in vivo. Science 289 5487 (2000) 2117-2120
53. Rodriguez F., Zhang J., and Whitton J.L. DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J Virol 71 11 (1997) 8497-8503
54. Delogu G., Howard A., Collins F.M., and Morris S.L. DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity. Infect Immun 68 6 (2000) 3097-3102
55. Glimcher L.H., Townsend M.J., Sullivan B.M., and Lord G.M. Recent developments in the transcriptional regulation of cytolytic effector cells. Nat Rev Immunol 4 11 (2004) 900-911
56. Kloetzel P.M., and Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol 16 1 (2004) 76-81
57. Strehl B., Seifert U., Kruger E., Heink S., Kuckelkorn U., and Kloetzel P.M. Interferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing. Immunol Rev 207 (2005) 19-30
58. Goodenow R.S., McMillan M., Nicolson M., Sher B.T., Eakle K., Davidson N., et al. Identification of the class I genes of the mouse major histocompatibility complex by DNA-mediated gene transfer. Nature 300 5889 (1982) 231-237
59. Nielsen M., Lundegaard C., Worning P., Lauemoller S.L., Lamberth K., Buus S., et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci 12 5 (2003) 1007-1017
60. Buus S., Lauemoller S.L., Worning P., Kesmir C., Frimurer T., Corbet S., et al. Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach. Tissue Antigens 62 5 (2003) 378-384
61. Courret N., Darche S., Sonigo P., Milon G., Buzoni-Gatel D., and Tardieux I. CD11c- and CD11b-expressing mouse leukocytes transport single Toxoplasma gondii tachyzoites to the brain. Blood 107 1 (2006) 309-316
62. Donnelly J.J., Wahren B., and Liu M.A. DNA vaccines: progress and challenges. J Immunol 175 2 (2005) 633-639